BofA upgraded Pharvaris (PHVS) to Neutral from Underperform with a price target of $27, up from $16.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Secures Registration Rights Agreement with General Atlantic
- Pharvaris Advances Clinical Pipeline with Strong Financials
- Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating
- Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position
- Pharvaris price target lowered to $52 from $55 at Citizens JMP